Canopy Growth CORP 8-K filings

Canopy Growth announced its first quarter fiscal year 2027 financial results, reporting a 13% increase in consolidated net revenue to $81.2 million and a 59% reduction in Adjusted EBITDA loss.

Canopy Growth Corporation announced its fiscal fourth quarter and full-year 2026 financial results, highlighting a 6% increase in consolidated net revenue for the full year to $284.6 million, driven by strong performance in its Canadian medical and adult-use cannabis segments.

Canopy Growth Corporation has adopted an Advance Notice By-Law to formalize director nominations, requiring specific disclosures and deadlines for shareholder nominations.

Canopy Growth Corporation announced it will restate previously issued financial statements for fiscal years 2024 and 2025 due to a non-cash technical accounting error related to share-settled warrants.

Canopy Growth Corporation has completed its acquisition of MTL Cannabis Corp., creating Canada's leading medical cannabis platform and strengthening its adult-use business.

Canopy Growth Corporation reported a 49% year-over-year reduction in net loss for Q3 FY2026, driven by strong Canadian cannabis sales and cost savings.

Canopy Growth Corporation announced strategic recapitalization transactions, including a new US$150 million senior secured loan and an exchange of C$96.4 million in convertible debentures, extending debt maturities to 2031 and enhancing liquidity.

Canopy Growth Corporation announced a definitive agreement to acquire MTL Cannabis Corp. for approximately C$125 million, aiming to create Canada's leading medical cannabis business and enhance global supply.

Canopy Growth reports improved Q2 FY2026 financial results with significant growth in Canada adult-use and medical cannabis revenue, alongside strengthened balance sheet and reduced Adjusted EBITDA loss.

Canopy Growth Corporation shareholders approved all four proposals at its Annual General and Special Meeting, including a significant share consolidation and the election of five directors.

Canopy Growth Corporation has officially appointed Thomas Stewart as its permanent Chief Financial Officer and Chief Accounting Officer, reinforcing its commitment to financial stability and operational discipline.

Canopy Growth Corporation announced a new at-the-market equity program to raise up to US$200 million, aiming to strengthen its financial position and fund strategic initiatives.

Canopy Growth Corporation reported a significant reduction in net loss and improved free cash flow in Q1 FY2026, driven by strong Canada adult-use cannabis sales and cost efficiencies, despite a decline in gross margin and Storz & Bickel revenue.

Canopy Growth Corporation announced an agreement with lenders to prepay US$50 million of its senior secured term loan by March 31, 2026, expected to reduce annual interest expense by US$6.5 million, while facilitating US$22 million in funding for Acreage Holdings.

Canopy Growth Corporation announced the immediate termination of its Chief Financial Officer, Judy Hong, and the appointment of Thomas Stewart as interim CFO, effective July 9, 2025.

Canopy Growth Corporation announced its Q4 and full fiscal year 2025 financial results, showcasing a significant reduction in total debt and a refined strategic focus on global medical cannabis and Canada adult-use market execution, despite a decline in net revenue and increased net loss.

Canopy Growth strengthens its balance sheet by making an optional early prepayment of US$100 million on its term loan, resulting in significant interest savings and extending the loan's maturity.

Canopy Growth Corporation has entered into an equity distribution agreement to sell up to $200 million of its common shares through an at-the-market offering.

Canopy Growth's Q3 FY2025 shows progress with strong growth in medical cannabis and Storz & Bickel, alongside the successful launch of Claybourne infused pre-rolls in Canada.

Canopy Growth Corporation has registered 7,631,637 common shares for resale by certain security holders, primarily related to recent debt settlements.

Canopy Growth Corporation has finalized the acquisition of Acreage Holdings through Canopy USA, marking a significant step in its U.S. expansion strategy.

Canopy Growth Corporation has announced the appointment of Luc Mongeau as its new Chief Executive Officer, succeeding David Klein, effective January 6, 2025.

Canopy Growth's Q2 FY2025 results show significant growth in key areas like Storz & Bickel and medical cannabis, alongside a strengthened balance sheet.

Canopy Growth has prepaid $100 million of its senior secured term loan at a discounted price, resulting in significant interest savings and an extended maturity date.

Canopy Growth Corporation held its 2024 Annual General Meeting where shareholders elected five directors, approved the appointment of PKF O'Connor Davies as auditor, and supported executive compensation on an advisory basis.

Canopy Growth Corporation has entered into retention agreements with its Chief Financial Officer and Chief Legal Officer, offering each a $150,000 bonus if they remain employed through October 1, 2025.

Canopy Growth Corporation announces CEO David Klein will retire by March 31, 2025, initiating a search for his successor.

Canopy Growth Corporation announced a 67% year-over-year increase in gross profit for the first quarter of fiscal year 2025, driven by cost reductions and a focus on higher-margin sales, despite a decrease in overall revenue.

Canopy Growth Corporation has entered into an equity distribution agreement to potentially sell up to $250 million of its common shares through at-the-market offerings in the U.S. and Canada.

Canopy Growth Corporation has filed a prospectus supplement to register the resale of 20,949,390 common shares by certain selling securityholders.